Caliber Wealth Management (Kansas)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.09M Buy
16,265
+750
+5% +$161K 0.4% 49
2026
Q1
$3.37M Buy
15,515
+628
+4% +$139K 0.37% 58
2025
Q4
$3.4M Buy
14,887
+611
+4% +$139K 0.37% 49
2025
Q3
$3.31M Buy
14,276
+553
+4% +$113K 0.37% 56
2025
Q2
$2.55M Buy
13,723
+12,608
+1,131% +$2.34M 0.27% 80
2025
Q1
$234K Buy
+1,115
New +$217K 0.03% 221

Other funds holding ABBV

Caliber Wealth Management (Kansas)'s ABBV Position: Q2 2026 in Review

Caliber Wealth Management (Kansas) increased its AbbVie (ABBV) stake by 4.8% in Q2 2026, buying an estimated $161K and bringing the position to 16,265 shares worth $4.09M. The position accounts for 0.4% of the portfolio, ranked #49.

Caliber Wealth Management (Kansas) first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. 2,360 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Caliber Wealth Management (Kansas) held 16,265 shares of AbbVie worth $4.09M as of Q2 2026.
  • Caliber Wealth Management (Kansas) bought 750 AbbVie shares in Q2 2026, an estimated $161K.
  • AbbVie made up 0.4% of Caliber Wealth Management (Kansas)'s portfolio in Q2 2026, its #49 holding.
  • Caliber Wealth Management (Kansas) first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
  • 2,360 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Caliber Wealth Management (Kansas)'s 13F filing for Q2 2026, filed 22 Jul 2026.